Mavyret® (glecaprevir/pibrentasvir) – New indication
June 11, 2025 - AbbVie announced the FDA approval of Mavyret (glecaprevir/pibrentasvir), for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection, without cirrhosis or with compensated cirrhosis (Child-Pugh A).
Top